Clinical Trial Search

Primary: the Comparison Between Treatment Groups of the Changes From Baseline in HbA1c at 48 Weeks — -1.8; -1.74; -1.47 percentage of HbA1c — p=<0.05

Primary: Change in Glycosylated Hemoglobin (HbA1c) From Baseline to Week 24 — -1.34; -1.62; -0.28 Percentage of hemoglobin — p=<0.001

Primary: Number of Patients With Treatment Failure — 203; 262; 287; 225 number of patients — p=0.0020

Primary: Fasting Insulin — 12.7; 13.1; 16.4; 13.9 μU/mL

Primary: Adjusted Change From Baseline in Glycated Hemoglobin A1c (HbA1c) at Week 28 — 0.11; 0.38 percentage (%HbA1c) — p=0.444

Primary: Change in Glycosylated Hemoglobin (HbA1c) From Baseline to Week 30 — -1.13; -1.10 percent of hemoglobin — p=0.6273

Primary: HbA1c Level — 6.9; 6.4 percentage of glycated hemoglobin

Primary: Change From Baseline in Body Weight — -6.16; -3.97 kg — p=0.0030

Primary: Effect on Functional Beta-cell Mass as Determined by Change in ß-cell Secretory Capacity at 6 Months (μU/ml) — 214; 149; 133; 188.5 μU/ml — p==0.1

Primary: Change in Time-averaged Glucose During a 24 Hour Period — -41.65; -29.56 mg/dL — p=<.001

Primary: Change in Glycosylated Hemoglobin (HbA1c) — -1.71; -1.00 percentage of hemoglobin — p=<0.001

Primary: Mean Plasma Glucose Area Under the Curve (AUC) for Blood Glucose Concentration in the Exenatide 1.25 mcg or Exenatide 2.5 mcg Treated Groups Along With Insulin, Compared…

Primary: Effect of Pioglitazone, Exenatide and Combined Pioglitazone and Exenatide on Body Weight — 5.5; 2.4; 2.7 kg — p=<0.05

Primary: Change in Glycosylated Hemoglobin (HbA1c) — -0.84; -0.10 Percentage — p=<0.001

Primary: Change in Glycosylated A1c (HbA1c) at Week 26 — -1.12; -0.79 percentage point of total HbA1c — p=<.0001

Primary: Change in Glcosylated Hemoglobin (HbA1c) — 8.59; 8.65; -0.98; -0.88 percentage — p=0.2534

Primary: The Percentage of Intent to Treat Participants Randomized and Treated in Each Arm Who Had Lab-measured A1c <6.5% at 24 Weeks of Treatment — 47; 12 percentage of…

Primary: Mean Daily Blood Glucose Concentration Inpatient — 177.1; 154.1; 166.1 mg/dL

Primary: Percent of Patients Who Achieved HbA1c ≤ 7.4% With Minimal Weight Gain (≤ 1kg) — 53.4; 19.8 percentage of participants — p=<0.001

Primary: Change in Glycosylated Hemoglobin (HbA1c) — -1.00; -1.14 Percentage of glycosylated hemoglobin — p=0.055

Primary: Percentage of Patients Experiencing Adverse Events — 73.1 percentage of patients

Primary: Change in HbA1c From Baseline to Week 26 — -1.55; -0.92; -1.23 percentage of total hemoglobin — p=<.0001

Primary: The Role of Exenatide as Compared to Insulin Monotherapy in Reducing Postprandial Hyperglycemia.

Primary: Change in ASIiAUC During a Hyperglycemic Clamp Test. — 643.40; 686.41; 786.12; 747.26 uIU-min/ml — p=0.282

Primary: Percentage of Patients Who Achieved Glycemic Target of HbA1c ≤ 7.0% With Minimal Weight Gain (≤ 1 Kg) at Month 12. — 35.0; 15.8 percentage of patients

Primary: Beta-cell Function After 52 Weeks of Therapy — 2.89; 1.15 ratio — p=0.0001

Primary: Hepatic Steatosis — 4.0 Percentage of liver fat

Primary: Treatment Failure (Loss of Glycemic Control) — 120; 90; 109; 112 participants

Primary: Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 12 — 0.46; 0.18; -0.07; 0.01 Percentage of HbA1c — p=0.061

Primary: Change in Glycosylated Hemoglobin (HbA1c) — 8.13; 8.19; -1.00; -1.05 percentage — p=0.4602